Correlation of Fine Needle Aspiration Cytology of Thyroid Gland with Histopathological Results

Machała, Ewa; Sopiński, Jan; Iavorska, Iulia; Kołomecki, Krzysztof

doi:10.5604/01.3001.0012.4712

Cited by 35 publications

(41 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As expected, our series were predominantly female (female to male; 4:1) with a comparable mean of age, which is in keeping with other studies [ 12 ]. Moreover, other parameters, including (BMI, Vit D, pre-op TSH, anti-thyroglobulin antibody, and anti-thyroid peroxidase antibody) showed almost no significant differences between both genders' groups.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

The Prevalence of Thyroid Papillary Microcarcinoma in Patients With Benign Thyroid Fine Needle Aspiration

Alshathry¹,

Almeshari²,

Alarifi³

et al. 2020

Cureus

View full text Add to dashboard Cite

Introduction Thyroid nodules are a very common clinical finding in the general population. We use fine needle aspiration (FNA) as the gold standard workup test for a thyroid nodule, as it is capable of differentiating malignant nodules from benign in the majority of cases. Usually, FNA is done for nodules that are more than 1 cm; small malignant lesions that are less than 1 cm in size can be missed. That's why the risk of having undiagnosed microcarcinomas in an otherwise benign FNA needs to be explored. Aim To estimate the prevalence of thyroid papillary microcarcinoma in patients with benign FNA and evaluate and correlate the FNA cytological results with the final histopathological diagnoses. Methods This was a retrospective study of 1543 post-thyroidectomy patients who underwent FNA cytology, were classified according to the Bethesda scoring system, and were admitted to two tertiary care hospitals in Riyadh, Saudi Arabia, from 2010 to 2019. Results Six-hundred-seven (607) out of 1543 FNA cytology results were reported as benign, 215 as malignant, and 73 as suspicious of malignancy. On final histopathology diagnosis, 81/607 (13.34%) of benign cases and 35/215 (16.28%) of malignant cases did not meet the initial cytology and were confirmed as papillary microcarcinoma. In patients with microcarcinoma after initial benign FNA (89.2%) found to have benign multinodular changes, compared to only (31%) of initial malignant FNA patients. Conclusion When non-surgical intervention is chosen in patients with benign FNA, the possibility of coexisting microcarcinoma with its variable prognosis should be taken into account and explained to the patient.

show abstract

Section: Discussionsupporting

confidence: 92%

“…The diagnostic accuracy of FNA to detect malignancy for thyroid lesions is 85.88%. Other studies reported 83.6% [29] to 89.46% [12] accuracy of FNA, which supports ours.…”

Section: Discussionsupporting

confidence: 91%

The Prevalence of Thyroid Papillary Microcarcinoma in Patients With Benign Thyroid Fine Needle Aspiration

Alshathry¹,

Almeshari²,

Alarifi³

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…In the study of Chieng J et al, FNAC predicted malignancy with a sensitivity, speci city, PPV, NPV, false positive rate, false negative rate and total accuracy of 90.7%, 53.6%, 43.3%, 93.7%, 46.4%, 9.3% and 64.1%, respectively [37]. However, FNAC is considered to be "uninterpretable" in 10 to 20% of cases or simply "suspicious" in 9 to 38% of cases [38].In addition, it is currently estimated that cytologically indeterminate results are diagnosed in up to 25% to 30% of thyroid biopsies [39,40].Therefore, the use of molecular markers is important for improving diagnostic accuracy. In this study, blood E2F3 mRNA predicted malignancy with a sensitivity, speci city, PPV, NPV, and accuracy of 90%, 60.9%, 70.5%, 85.47%, and 74.4%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of peripheral blood E2F3 mRNA as a potential diagnostic biomarker in human papillary thyroid cancer

Zhao¹,

Zhao²,

Wu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The transcription factor E2F3 plays a vital role in regulating cell cycle progression and proliferation. In addition, many reports have shown that E2F3 exerts an oncogenic role in various cancers and is a promising therapeutic target for the treatment of some human cancers. However, the value of E2F3 in the molecular diagnosis and prognosis evaluation of papillary thyroid cancer (PTC) has rarely been reported. The aim of this study was to evaluate the clinical signiﬁcance of E2F3 in the early diagnosis and monitoring of PTC.Materials and methods: Peripheral blood samples from 20 patients with PTC, 20 patients with benign thyroid lesions and 20 normal controls were collected. Peripheral blood E2F3 mRNA and thyroid sample E2F3 mRNA expression were detected by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). The expression of E2F3 protein in normal thyroid tissue and thyroid tissue from benign thyroid lesions and PTC were detected by immunohistochemistry. The optimal cut-off value for differentiating PTC was obtained by using receiver operating characteristic (ROC) curve analysis.Results: E2F3 mRNA expression levels in peripheral blood and thyroid samples were significantly higher in PTC patients than in patients with benign thyroid lesions and normal subjects (P<0.05). Moreover, benign hyperplasia had higher E2F3 expression than normal tissue (P<0.01).There was no significant association between the level of E2F3 mRNA and aggressive clinicopathologic features of PTC, including TNM staging, extrathyroidal invasion, multifocality, and lymph node metastasis (P>0.05).With a cut-off value of 2.3, blood E2F3 mRNA showed 90% sensitivity, 60.9% specificity, a 70.5% positive predictive value, an 85.47% negative predictive value and 74.4% accuracy for discriminating PTC from benign hyperplasia disease of the thyroid and normal tissue. In addition, immunohistochemical results showed that E2F3 protein expression was also higher in the PTC group than in the other groups.Conclusions: The highest expression of E2F3 was found in peripheral blood and thyroid tissue of PTC patients. Moreover, blood E2F3 mRNA can be considered a promising diagnostic marker for discriminating PTC from benign thyroid diseases.

show abstract

“…Those changes led a significant decrease in surgery rates when compared with the period before TBSRTC without any decrease in malignancy rates 5 . The benefit of TBSRTC has been represented by several studies and metaanalyses [6][7][8][9] . However, TBSRTC alone may fail in decision making particularly in intermediate (III, IV and V) categories and adjunct diagnostic methods such as repeating FNAB, molecular testing and lobectomy have been recommended for more accurate diagnosis [10][11] .…”

Section: Introductionmentioning

confidence: 99%

Comparison of the Bethesda system classification and postoperative cytology of thyroid nodules: A single center experience

Özdenkaya¹,

Ersavas²,

Ölmüşçelik³

et al. 2019

Dicle Tıp Dergisi

View full text Add to dashboard Cite

Objective: Recent American Thyroid Association Guideline emphasizes that identifying the institutional malignancy risks for each Bethesda category is mandatory to achieve more accurate preoperative diagnosis in thyroid nodules. Aim of this study is to compare the preoperative fine needle aspiration biopsy (FNAB) and postoperative pathology results in a single institution in the era of the Bethesda System for Reporting thyroid Cytology (TBSRTC). Methods: The data of the patients who underwent FNAB and thyroidectomy between 2012 and 2018 were collected retrospectively. Patients who had available TBSRTC classification were included in the study. The malignancy risk of each TBSRTC classification was calculated. Results: One-hundred and forty-five patients were included. The mean age was 45.9±13.6. Preoperative FNAB categorization was TBSRTC I in 3 (2.1%) patients, TBSRTC II in 47 (32.4%) patients, TBSRTC III 16 (11%) patients, TBSRTC IV in 14 (9.7%) patients, TBSRTC V in 29 (20%) and VI in 36 (24.8%) patients. Postoperative pathology revealed malignancy in 66 (45.5%) of the patients. The malignancy risk was 33.3% in TBSRTC I, 4.3% in TBSRTC II, 31.3% in TBSRTC III, 42.9% in TBSRTC IV, 62.1% in TBSRTC V and 94.4% in TBSRTC VI categories. Conclusion: Our results were conformable with the malignancy risks reported by TBSRTC. Larger studies should be performed to validate and endorse nationwide standardization of the Bethesda system.

show abstract

Correlation of Fine Needle Aspiration Cytology of Thyroid Gland with Histopathological Results

Cited by 35 publications

References 0 publications

The Prevalence of Thyroid Papillary Microcarcinoma in Patients With Benign Thyroid Fine Needle Aspiration

The Prevalence of Thyroid Papillary Microcarcinoma in Patients With Benign Thyroid Fine Needle Aspiration

Evaluation of peripheral blood E2F3 mRNA as a potential diagnostic biomarker in human papillary thyroid cancer

Comparison of the Bethesda system classification and postoperative cytology of thyroid nodules: A single center experience

Contact Info

Product

Resources

About